The aim of this study was to investigate a possible association between the use of SGLT2 inhibitors and inner ear dysfunction, primarily in the form of sensorineural hearing loss, which may in part be related to microvascular damage. The gene discussed is SLC5A2; the disease is hearing loss disorder.